RxDoctor Payments Data

Kari Jensen-Seaman

Family · Mc Murray, PANPI 1477035152

Payments from drug & device makers

$316in general payments, 2019–2025

Across 18 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$57
  • GSK$49
  • Esperion Therapeutics, Inc.$42
  • Biohaven Pharmaceuticals, Inc.$39
  • Novo Nordisk$32
  • Currax Pharmaceuticals LLC$27
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$316 in reported general payments places this provider in the 45th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$31,407
Medicare patients
48
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$80,441
JardianceEmpagliflozin30$25,051
TrulicityDulaglutide14$14,674
LinzessLinaclotide16$9,798
TradjentaLinagliptin15$8,175
JanuviaSitagliptin Phosphate11$7,194
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$6,990
Memantine Hcl48$6,907
RhopressaNetarsudil Mesylate11$3,694
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$3,622
Atorvastatin Calcium106$3,486
Carbidopa-Levodopa ErCarbidopa/Levodopa11$2,761
Sertraline Hcl107$2,579
Donepezil Hcl60$2,465
Amiodarone Hcl13$2,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$80,441145 claims
AbbVieLinzess$27$9,79816 claims
GSKTrelegy Ellipta$49$6,99015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,717 family providers in Pennsylvania.

Other family in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →